Alterations in Lymphocytic Metabolism—An Emerging Hallmark of MS Pathophysiology?

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) characterised by acute inflammation and subsequent neuro-axonal degeneration resulting in progressive neurological impairment. Aberrant immune system activation in the periphery and subsequent lymphocyte migration to the CNS contribute to the pathophysiology. Recent research has identified metabolic dysfunction as an additional feature of MS. It is already well known that energy deficiency in neurons caused by impaired mitochondrial oxidative phosphorylation results in ionic imbalances that trigger degenerative pathways contributing to white and grey matter atrophy. However, metabolic dysfunction in MS appears to be more widespread than the CNS. This review focuses on recent research assessing the metabolism and mitochondrial function in peripheral immune cells of MS patients and lymphocytes isolated from murine models of MS. Emerging evidence suggests that pharmacological modulation of lymphocytic metabolism may regulate their subtype differentiation and rebalance pro- and anti-inflammatory functions. As such, further understanding of MS immunometabolism may aid the identification of novel treatments to specifically target proinflammatory immune responses.

[1]  A. Melnichenko,et al.  Significance of Mitochondrial Dysfunction in the Progression of Multiple Sclerosis , 2022, International journal of molecular sciences.

[2]  D. Jiao,et al.  Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity , 2022, Journal of Hematology & Oncology.

[3]  K. Dhama,et al.  Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders – Advances and challenges , 2022, Human vaccines & immunotherapeutics.

[4]  Nicole M. Chapman,et al.  Metabolic adaptation of lymphocytes in immunity and disease. , 2022, Immunity.

[5]  C. Manosalva,et al.  Role of Lactate in Inflammatory Processes: Friend or Foe , 2022, Frontiers in Immunology.

[6]  L. O’Neill,et al.  The role of the electron transport chain in immunity , 2021, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  F. Zipp,et al.  Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity , 2021, Brain : a journal of neurology.

[8]  A. Regev,et al.  Metabolic modeling of single Th17 cells reveals regulators of autoimmunity , 2021, Cell.

[9]  B. Hall,et al.  Multiple sclerosis patients have reduced resting and increased activated CD4+CD25+FOXP3+T regulatory cells , 2021, Scientific Reports.

[10]  L. Poisson,et al.  Blood-based untargeted metabolomics in relapsing-remitting multiple sclerosis revealed the testable therapeutic target , 2018, bioRxiv.

[11]  E. Leray,et al.  Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition , 2020, Multiple sclerosis.

[12]  G. Garinis,et al.  Mitochondrial Oxidative Damage Underlies Regulatory T Cell Defects in Autoimmunity. , 2020, Cell metabolism.

[13]  Ayelet Armon-Omer,et al.  Mitochondrial activity is impaired in lymphocytes of MS patients in correlation with disease severity. , 2020, Multiple sclerosis and related disorders.

[14]  Jeffrey A. Cohen,et al.  Advances in oral immunomodulating therapies in relapsing multiple sclerosis , 2020, The Lancet Neurology.

[15]  G. Brooks Lactate as a fulcrum of metabolism , 2020, Redox biology.

[16]  R. Satija,et al.  Niche-Selective Inhibition of Pathogenic Th17 Cells by Targeting Metabolic Redundancy , 2019, Cell.

[17]  M. Kúdelová,et al.  T cells and their function in the immune response to viruses. , 2020, Acta virologica.

[18]  P. Pinton,et al.  Mitochondrial functionality and metabolism in T cells from progressive multiple sclerosis patients , 2019, European journal of immunology.

[19]  M. Ruscica,et al.  Lactate Buildup at the Site of Chronic Inflammation Promotes Disease by Inducing CD4+ T Cell Metabolic Rewiring , 2019, Cell metabolism.

[20]  G. Campbell,et al.  Targeting mitochondria to protect axons in progressive MS , 2019, Neuroscience Letters.

[21]  A. Tänzer Molecular Mechanisms of Immunometabolic Dysfunction in Multiple Sclerosis , 2019 .

[22]  M. Portero-Otín,et al.  Impairment of Mitochondrial Redox Status in Peripheral Lymphocytes of Multiple Sclerosis Patients , 2019, Front. Neurosci..

[23]  Nicole M. Chapman,et al.  Metabolic coordination of T cell quiescence and activation , 2019, Nature Reviews Immunology.

[24]  S. Weinberg,et al.  Requirement of Mitochondrial Transcription Factor A in Tissue-Resident Regulatory T Cell Maintenance and Function , 2019, Cell reports.

[25]  J. Graves,et al.  Mitochondrial Dysfunction and Multiple Sclerosis , 2019, Biology.

[26]  Shuai Jiang,et al.  Mitochondrial electron transport chain, ROS generation and uncoupling (Review) , 2019, International journal of molecular medicine.

[27]  A. Bar-Or,et al.  Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects , 2019, Science Translational Medicine.

[28]  Robert C Reiner,et al.  Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2019, The Lancet Neurology.

[29]  B. Moran,et al.  Differential Regulation of Human Treg and Th17 Cells by Fatty Acid Synthesis and Glycolysis , 2019, Front. Immunol..

[30]  H. Lassmann Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis , 2019, Front. Immunol..

[31]  M. Mehta,et al.  Mitochondrial complex III is essential for suppressive function of regulatory T cells , 2019, Nature.

[32]  H. Ullum,et al.  Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk , 2018, Cell.

[33]  P. Schaik,et al.  Inflammation and mitochondrial dysfunction: A vicious circle in neurodegenerative disorders? , 2017, Neuroscience Letters.

[34]  Beisi Xu,et al.  Metabolic heterogeneity underlies reciprocal fates of TH17 cell stemness and plasticity , 2018, Nature.

[35]  H. Ullum,et al.  Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk , 2018, Cell.

[36]  F. Baig,et al.  Mitochondrial dysfunction and increased glycolysis in prodromal and early Parkinson's blood cells , 2018, Movement disorders : official journal of the Movement Disorder Society.

[37]  M. Teitell,et al.  Initial B Cell Activation Induces Metabolic Reprogramming and Mitochondrial Remodeling , 2018, iScience.

[38]  D. M. Smith,et al.  Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis , 2018, Immunity.

[39]  D. Mahad,et al.  Mitochondrial dysfunction and axon degeneration in progressive multiple sclerosis , 2018, FEBS letters.

[40]  Clare Baecher-Allan,et al.  Multiple Sclerosis: Mechanisms and Immunotherapy , 2018, Neuron.

[41]  D. Farber,et al.  Human T Cell Development, Localization, and Function throughout Life. , 2018, Immunity.

[42]  H. Young,et al.  Early TCR Signaling Induces Rapid Aerobic Glycolysis Enabling Distinct Acute T Cell Effector Functions , 2018, Cell reports.

[43]  S. Heales,et al.  Blood Mononuclear Cell Mitochondrial Respiratory Chain Complex IV Activity is Decreased in Multiple Sclerosis Patients: Effects of β-Interferon Treatment , 2018, Journal of clinical medicine.

[44]  L. Galluzzi,et al.  The spectrum of T cell metabolism in health and disease , 2017, Nature Reviews Immunology.

[45]  David S. Park,et al.  Guidelines on experimental methods to assess mitochondrial dysfunction in cellular models of neurodegenerative diseases , 2017, Cell Death & Differentiation.

[46]  D. Centonze,et al.  Immunometabolic profiling of T cells from patients with relapsing-remitting multiple sclerosis reveals an impairment in glycolysis and mitochondrial respiration , 2017, Metabolism: clinical and experimental.

[47]  Theodore V. Tselios,et al.  Multiple Sclerosis: Immunopathology and Treatment Update , 2017, Brain sciences.

[48]  A. Gaultier,et al.  Lineage-Specific Metabolic Properties and Vulnerabilities of T Cells in the Demyelinating Central Nervous System , 2017, The Journal of Immunology.

[49]  D. Wallace,et al.  Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments. , 2017, Cell metabolism.

[50]  L. Figueiredo Faculty Opinions recommendation of HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. , 2017 .

[51]  L. Morel Immunometabolism in systemic lupus erythematosus , 2017, Nature Reviews Rheumatology.

[52]  G. Trianni,et al.  Metabolic response to glatiramer acetate therapy in multiple sclerosis patients , 2016, BBA clinical.

[53]  D. Veale,et al.  Hypoxia, mitochondrial dysfunction and synovial invasiveness in rheumatoid arthritis , 2016, Nature Reviews Rheumatology.

[54]  Li Guo,et al.  Metformin ameliorates the development of experimental autoimmune encephalomyelitis by regulating T helper 17 and regulatory T cells in mice , 2016, Journal of Neuroimmunology.

[55]  M. Memo,et al.  Mitochondrial Alterations in Peripheral Mononuclear Blood Cells from Alzheimer's Disease and Mild Cognitive Impairment Patients , 2016, Oxidative medicine and cellular longevity.

[56]  Sean C. Sapcariu,et al.  Pro-inflammatory Macrophages Sustain Pyruvate Oxidation through Pyruvate Dehydrogenase for the Synthesis of Itaconate and to Enable Cytokine Expression , 2015, The Journal of Biological Chemistry.

[57]  V. De Rosa,et al.  Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants , 2015, Nature Immunology.

[58]  J. Redondo,et al.  Mitochondrial Respiration Controls Lysosomal Function during Inflammatory T Cell Responses. , 2015, Cell metabolism.

[59]  G. Trianni,et al.  Bioenergetics profile of CD4(+) T cells in relapsing remitting multiple sclerosis subjects. , 2015, Journal of biotechnology.

[60]  Abhishek K. Jha,et al.  Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. , 2015, Immunity.

[61]  J. Ioannidis,et al.  Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses , 2015, The Lancet Neurology.

[62]  J. Locasale,et al.  Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation. , 2015, The Journal of clinical investigation.

[63]  H. Lassmann,et al.  Mitochondrial dysfunction contributes to neurodegeneration in multiple sclerosis. , 2014, Trends in molecular medicine.

[64]  M. Teitell,et al.  Techniques to monitor glycolysis. , 2014, Methods in enzymology.

[65]  F. Quintana,et al.  [Immunopathology of multiple sclerosis]. , 2014, Medicina.

[66]  G. Cutter,et al.  Natural history of multiple sclerosis symptoms. , 2013, International journal of MS care.

[67]  M. Pirinen,et al.  Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis , 2013, Nature Genetics.

[68]  B. Faubert,et al.  Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis , 2013, Cell.

[69]  D. Hafler,et al.  Specific peripheral B cell tolerance defects in patients with multiple sclerosis. , 2013, The Journal of clinical investigation.

[70]  H. Wiendl,et al.  Fine-Tuning of Regulatory T Cell Function: The Role of Calcium Signals and Naive Regulatory T Cells for Regulatory T Cell Deficiency in Multiple Sclerosis , 2013, The Journal of Immunology.

[71]  R. Gamelli,et al.  Genomic responses in mouse models poorly mimic human inflammatory diseases , 2013, Proceedings of the National Academy of Sciences.

[72]  D. Geerts,et al.  Reduced expression of PGC-1α partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex , 2013, Acta Neuropathologica.

[73]  V. Nociti,et al.  Type 1 immune response in progressive multiple sclerosis , 2012, Journal of Neuroimmunology.

[74]  H. Lassmann,et al.  Explorer NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury , 2012 .

[75]  M. V. Vander Heiden,et al.  Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. , 2011, Annual review of cell and developmental biology.

[76]  D. Turnbull,et al.  Increased mitochondrial content in remyelinated axons: implications for multiple sclerosis. , 2011, Brain : a journal of neurology.

[77]  R. Clements,et al.  Analysis of the mitochondrial proteome in multiple sclerosis cortex. , 2011, Biochimica et biophysica acta.

[78]  M. Brand,et al.  Assessing mitochondrial dysfunction in cells , 2011, The Biochemical journal.

[79]  J. Rathmell,et al.  Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets , 2011, The Journal of Immunology.

[80]  Richard Reynolds,et al.  Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis , 2011, Annals of neurology.

[81]  G. Disanto,et al.  Heterogeneity in Multiple Sclerosis: Scratching the Surface of a Complex Disease , 2010, Autoimmune diseases.

[82]  J. Geurts,et al.  Enhanced number and activity of mitochondria in multiple sclerosis lesions , 2009, The Journal of pathology.

[83]  P. Hanson,et al.  Edinburgh Research Explorer Mitochondrial Changes within Axons in Multiple Sclerosis Mitochondrial Changes within Axons in Multiple Sclerosis , 2022 .

[84]  A. Pandit,et al.  Impaired regulation of electron transport chain subunit genes by nuclear respiratory factor 2 in multiple sclerosis , 2009, Journal of the Neurological Sciences.

[85]  T. Nomura,et al.  Regulatory T Cells and Immune Tolerance , 2008, Cell.

[86]  Hans Lassmann,et al.  Mitochondrial defects in acute multiple sclerosis lesions , 2008, Brain : a journal of neurology.

[87]  G. Crooks,et al.  Immune-cell lineage commitment: translation from mice to humans. , 2007, Immunity.

[88]  G. Freeman,et al.  Innate Immunity in Multiple Sclerosis: Myeloid Dendritic Cells in Secondary Progressive Multiple Sclerosis Are Activated and Drive a Proinflammatory Immune Response1 , 2006, The Journal of Immunology.

[89]  R. Rudick,et al.  Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients , 2006, Annals of neurology.

[90]  P. Krammer,et al.  Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis , 2005, European journal of immunology.

[91]  R. Toes,et al.  Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells. , 2005, Arthritis and rheumatism.

[92]  Fahmeed Hyder,et al.  Energetic basis of brain activity: implications for neuroimaging , 2004, Trends in Neurosciences.

[93]  Jia Newcombe,et al.  Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[94]  H. Link,et al.  Circulating CD4+CD25+ T Regulatory Cells Are Not Altered in Multiple Sclerosis and Unaffected by Disease-Modulating Drugs , 2004, Journal of Clinical Immunology.

[95]  Shimon Sakaguchi,et al.  IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. , 2004, International immunology.

[96]  S. Miller,et al.  EncephalomyelitisExperimental Autoimmune System Inflammation During Active Immune Responses and Central Nervous Cells Suppress Antigen-Specific Autoreactive Regulatory T + CD25+ Cutting Edge: CD4 , 2022 .

[97]  Steven J. Sollott,et al.  Reactive Oxygen Species (Ros-Induced) Ros Release , 2000, The Journal of experimental medicine.

[98]  S. Croul,et al.  Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis , 2000, Journal of the Neurological Sciences.

[99]  H. Weiner,et al.  Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[100]  C. Boitard,et al.  T cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice , 1989, The Journal of experimental medicine.